IE
GLUE icon

Israel Englander’s Monte Rosa Therapeutics GLUE Stock Holding History

Israel Englander’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-191,382
Closed -$3.15M – 6068
2026
Q1 		$3.15M Buy
191,382
+87,410
+84% +$1.67M ﹤0.01% 3428
2025
Q4 		$1.63M Sell
103,972
-340,967
-77% -$4.59M ﹤0.01% 4111
2025
Q3 		$3.3M Buy
444,939
+380,308
+588% +$2.01M ﹤0.01% 3557
2025
Q2 		$291K Sell
64,631
-265,836
-80% -$1.19M ﹤0.01% 5205
2025
Q1 		$1.53M Buy
330,467
+284,097
+613% +$1.74M ﹤0.01% 4020
2024
Q4 		$322K Buy
46,370
+15,749
+51% +$118K ﹤0.01% 5035
2024
Q3 		$162K Buy
30,621
+9,693
+46% +$48.9K ﹤0.01% 5498
2024
Q2 		$78.3K Sell
20,928
-129,097
-86% -$658K ﹤0.01% 5349
2024
Q1 		$1.06M Buy
150,025
+82,746
+123% +$491K ﹤0.01% 4244
2023
Q4 		$380K Buy
+67,279
New +$264K ﹤0.01% 4820
2023
Q2 		– Sell
-117,094
Closed -$912K – 6314
2023
Q1 		$912K Sell
117,094
-276,056
-70% -$1.92M ﹤0.01% 4179
2022
Q4 		$2.99M Buy
393,150
+367,221
+1,416% +$3.06M ﹤0.01% 3216
2022
Q3 		$212K Buy
25,929
+8,526
+49% +$78.3K ﹤0.01% 5620
2022
Q2 		$168K Buy
+17,403
New +$175K ﹤0.01% 5718
2021
Q4 		– Sell
-175,445
Closed -$3.91M – 7008
2021
Q3 		$3.91M Sell
175,445
-59,657
-25% -$1.71M ﹤0.01% 3154
2021
Q2 		$5.34M Buy
+235,102
New +$4.79M ﹤0.01% 2671

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Israel Englander's GLUE Position: Q2 2026 in Review

Israel Englander sold out of Monte Rosa Therapeutics (GLUE) in Q2 2026, closing a stake of 191,382 shares — an estimated $3.15M sold.

Israel Englander first reported a position in GLUE in Q2 2021 and held it in 16 quarters. The position peaked at $5.34M in Q2 2021. 191 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Israel Englander reported no remaining Monte Rosa Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Israel Englander sold 191,382 Monte Rosa Therapeutics shares in Q2 2026, an estimated $3.15M.
  • Israel Englander first reported a position in Monte Rosa Therapeutics in Q2 2021 and held it in 16 quarters.
  • Israel Englander's Monte Rosa Therapeutics position peaked at $5.34M in Q2 2021.
  • 191 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.